Cytoreductive Surgery plus Hyperthermic Intraperitoneal Chemotherapy with Lobaplatin and Docetaxel to Treat Synchronous Peritoneal Carcinomatosis from Gastric Cancer: Results from a Chinese Center
Abstract Background This work was to evaluate the efficacy and safety of cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) with lobaplatin and docetaxel to treat peritoneal carcinomatosis (PC) from gastric cancer (GC). Methods A total of 50 consecutive GC PC patients...
Gespeichert in:
| Veröffentlicht in: | European journal of surgical oncology 2016-07, Vol.42 (7), p.1024-1034 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1034 |
|---|---|
| container_issue | 7 |
| container_start_page | 1024 |
| container_title | European journal of surgical oncology |
| container_volume | 42 |
| creator | Wu, Hai-Tao, MD Peng, Kai-Wen, MD Ji, Zhong-He, MD Sun, Jian-Hua, MD Zhang, Qian, MD Yang, Xiao-Jun, MD, PhD Huang, Chao-Qun, MD, PhD Li, Yan, MD, PhD |
| description | Abstract Background This work was to evaluate the efficacy and safety of cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) with lobaplatin and docetaxel to treat peritoneal carcinomatosis (PC) from gastric cancer (GC). Methods A total of 50 consecutive GC PC patients treated by 52 CRS+HIPEC procedures with lobaplatin 50 mg/m2 and docetaxel 60 mg/m2 in 6,000 mL of normal saline at (43±0.5) °C for 60 min. The primary endpoint was overall survival (OS), and the secondary endpoints were perioperative safety profiles. Results At the median follow-up of 22.5 (range, 5.1-50.7) months, the median OS was 14.3 (95% CI 7.6-21.0) months, and the 1-, 2-, and 3-year survival rates were 58%, 40%, and 32%, respectively. Mortality and serious adverse event (grade 3-5) morbidity rates in postoperative 30 days were 0.0% and 23.1%, respectively. Univariate analysis identified 4 parameters with significant effects on OS: completeness of cytoreduction (CC)0-1, normal (N) the preoperative tumor markers level (TM), adjuvant chemotherapy ≥6 cycles, and peritoneal cancer index ≤20. However, multivariate analysis identified CC0-1, perioperative TM (N), adjuvant chemotherapy ≥6 cycles as the independent predictor for better survival. Conclusions CRS+HIPEC with lobaplatin and docetaxel to treat selected GC PC could improve OS, with acceptable perioperative safety. |
| doi_str_mv | 10.1016/j.ejso.2016.04.053 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1804196786</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0748798316301147</els_id><sourcerecordid>1804196786</sourcerecordid><originalsourceid>FETCH-LOGICAL-c455t-132214061231bbcb8b8d4db34d12be7a6397f003b4863bb920f29b772a58197f3</originalsourceid><addsrcrecordid>eNp9Us2O0zAQthCIXQovwAH5yKXFP0mcIISEAuyuVAlEl7NlO1PqktjBdhbyfjwYjloQ4sDJY30_o5lvEHpKyYYSWr04buAY_YblekOKDSn5PXRJS87WjJbiProkoqjXoqn5BXoU45EQ0nDRPEQXTFDRNKy4RD_bOfkA3WSSvQO8m8IXCDMe-yni63mEkA4QBmvwjUtB5b9N3oHqcXuAwS-gGmf83aYD3nqtxl4l67ByHX7rDST1A3qcPL4NoBLezc4cgnc-m3_8y0oFY50fVPLRRrwPfsBXKqaQ27bKGQgv8SeIU5_OoMrdrYMIuAWXIDxGD_aqj_Dk_K7Q5_fvbtvr9fbD1U37Zrs2RVmmNeWM0YJUlHGqtdG1rrui07zoKNMgVMUbsSeE66KuuNYNI3vWaCGYKmuaIb5Cz0--Y_DfJohJDjYa6HvlIM8kaU0K2lQiy1eInagm-BgD7OUY7KDCLCmRS3ryKJf05JKeJIXM6WXRs7P_pAfo_kh-x5UJr04EyFPeWQgyGgt5Q50NYJLsvP2__-t_5Ka3zhrVf4UZ4tFPweX9SSojk0TulvtZzodWnFBaCP4LdbXFWA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1804196786</pqid></control><display><type>article</type><title>Cytoreductive Surgery plus Hyperthermic Intraperitoneal Chemotherapy with Lobaplatin and Docetaxel to Treat Synchronous Peritoneal Carcinomatosis from Gastric Cancer: Results from a Chinese Center</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><creator>Wu, Hai-Tao, MD ; Peng, Kai-Wen, MD ; Ji, Zhong-He, MD ; Sun, Jian-Hua, MD ; Zhang, Qian, MD ; Yang, Xiao-Jun, MD, PhD ; Huang, Chao-Qun, MD, PhD ; Li, Yan, MD, PhD</creator><creatorcontrib>Wu, Hai-Tao, MD ; Peng, Kai-Wen, MD ; Ji, Zhong-He, MD ; Sun, Jian-Hua, MD ; Zhang, Qian, MD ; Yang, Xiao-Jun, MD, PhD ; Huang, Chao-Qun, MD, PhD ; Li, Yan, MD, PhD</creatorcontrib><description>Abstract Background This work was to evaluate the efficacy and safety of cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) with lobaplatin and docetaxel to treat peritoneal carcinomatosis (PC) from gastric cancer (GC). Methods A total of 50 consecutive GC PC patients treated by 52 CRS+HIPEC procedures with lobaplatin 50 mg/m2 and docetaxel 60 mg/m2 in 6,000 mL of normal saline at (43±0.5) °C for 60 min. The primary endpoint was overall survival (OS), and the secondary endpoints were perioperative safety profiles. Results At the median follow-up of 22.5 (range, 5.1-50.7) months, the median OS was 14.3 (95% CI 7.6-21.0) months, and the 1-, 2-, and 3-year survival rates were 58%, 40%, and 32%, respectively. Mortality and serious adverse event (grade 3-5) morbidity rates in postoperative 30 days were 0.0% and 23.1%, respectively. Univariate analysis identified 4 parameters with significant effects on OS: completeness of cytoreduction (CC)0-1, normal (N) the preoperative tumor markers level (TM), adjuvant chemotherapy ≥6 cycles, and peritoneal cancer index ≤20. However, multivariate analysis identified CC0-1, perioperative TM (N), adjuvant chemotherapy ≥6 cycles as the independent predictor for better survival. Conclusions CRS+HIPEC with lobaplatin and docetaxel to treat selected GC PC could improve OS, with acceptable perioperative safety.</description><identifier>ISSN: 0748-7983</identifier><identifier>EISSN: 1532-2157</identifier><identifier>DOI: 10.1016/j.ejso.2016.04.053</identifier><identifier>PMID: 27179924</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols - adverse effects ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Carcinoma - drug therapy ; Carcinoma - mortality ; Carcinoma - secondary ; Carcinoma - surgery ; Chemotherapy, Cancer, Regional Perfusion ; China ; Cyclobutanes - administration & dosage ; Cytoreduction Surgical Procedures ; Cytoreductive surgery ; Databases, Factual ; Docetaxel ; Female ; Follow-Up Studies ; Gastric cancer ; Hematology, Oncology and Palliative Medicine ; Humans ; Hyperthermia, Induced ; Hyperthermic intraperitoneal chemotherapy ; Kaplan-Meier Estimate ; Lobaplatin ; Lymphatic Metastasis ; Male ; Middle Aged ; Neoplasm Invasiveness ; Neoplasm Recurrence, Local ; Neoplasm Staging ; Neoplasms, Multiple Primary - drug therapy ; Neoplasms, Multiple Primary - mortality ; Neoplasms, Multiple Primary - surgery ; Organoplatinum Compounds - administration & dosage ; Peritoneal Neoplasms - drug therapy ; Peritoneal Neoplasms - mortality ; Peritoneal Neoplasms - secondary ; Peritoneal Neoplasms - surgery ; Prognosis ; Retrospective Studies ; Sample Size ; Stomach Neoplasms - pathology ; Surgery ; Synchronous peritoneal carcinomatosis ; Taxoids - administration & dosage ; Treatment Outcome</subject><ispartof>European journal of surgical oncology, 2016-07, Vol.42 (7), p.1024-1034</ispartof><rights>2016 The Author(s)</rights><rights>Copyright © 2016 The Author(s). Published by Elsevier Ltd.. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c455t-132214061231bbcb8b8d4db34d12be7a6397f003b4863bb920f29b772a58197f3</citedby><cites>FETCH-LOGICAL-c455t-132214061231bbcb8b8d4db34d12be7a6397f003b4863bb920f29b772a58197f3</cites><orcidid>0000-0001-6018-6538</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.ejso.2016.04.053$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27179924$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wu, Hai-Tao, MD</creatorcontrib><creatorcontrib>Peng, Kai-Wen, MD</creatorcontrib><creatorcontrib>Ji, Zhong-He, MD</creatorcontrib><creatorcontrib>Sun, Jian-Hua, MD</creatorcontrib><creatorcontrib>Zhang, Qian, MD</creatorcontrib><creatorcontrib>Yang, Xiao-Jun, MD, PhD</creatorcontrib><creatorcontrib>Huang, Chao-Qun, MD, PhD</creatorcontrib><creatorcontrib>Li, Yan, MD, PhD</creatorcontrib><title>Cytoreductive Surgery plus Hyperthermic Intraperitoneal Chemotherapy with Lobaplatin and Docetaxel to Treat Synchronous Peritoneal Carcinomatosis from Gastric Cancer: Results from a Chinese Center</title><title>European journal of surgical oncology</title><addtitle>Eur J Surg Oncol</addtitle><description>Abstract Background This work was to evaluate the efficacy and safety of cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) with lobaplatin and docetaxel to treat peritoneal carcinomatosis (PC) from gastric cancer (GC). Methods A total of 50 consecutive GC PC patients treated by 52 CRS+HIPEC procedures with lobaplatin 50 mg/m2 and docetaxel 60 mg/m2 in 6,000 mL of normal saline at (43±0.5) °C for 60 min. The primary endpoint was overall survival (OS), and the secondary endpoints were perioperative safety profiles. Results At the median follow-up of 22.5 (range, 5.1-50.7) months, the median OS was 14.3 (95% CI 7.6-21.0) months, and the 1-, 2-, and 3-year survival rates were 58%, 40%, and 32%, respectively. Mortality and serious adverse event (grade 3-5) morbidity rates in postoperative 30 days were 0.0% and 23.1%, respectively. Univariate analysis identified 4 parameters with significant effects on OS: completeness of cytoreduction (CC)0-1, normal (N) the preoperative tumor markers level (TM), adjuvant chemotherapy ≥6 cycles, and peritoneal cancer index ≤20. However, multivariate analysis identified CC0-1, perioperative TM (N), adjuvant chemotherapy ≥6 cycles as the independent predictor for better survival. Conclusions CRS+HIPEC with lobaplatin and docetaxel to treat selected GC PC could improve OS, with acceptable perioperative safety.</description><subject>Adult</subject><subject>Aged</subject><subject>Antineoplastic Combined Chemotherapy Protocols - adverse effects</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Carcinoma - drug therapy</subject><subject>Carcinoma - mortality</subject><subject>Carcinoma - secondary</subject><subject>Carcinoma - surgery</subject><subject>Chemotherapy, Cancer, Regional Perfusion</subject><subject>China</subject><subject>Cyclobutanes - administration & dosage</subject><subject>Cytoreduction Surgical Procedures</subject><subject>Cytoreductive surgery</subject><subject>Databases, Factual</subject><subject>Docetaxel</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Gastric cancer</subject><subject>Hematology, Oncology and Palliative Medicine</subject><subject>Humans</subject><subject>Hyperthermia, Induced</subject><subject>Hyperthermic intraperitoneal chemotherapy</subject><subject>Kaplan-Meier Estimate</subject><subject>Lobaplatin</subject><subject>Lymphatic Metastasis</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Neoplasm Invasiveness</subject><subject>Neoplasm Recurrence, Local</subject><subject>Neoplasm Staging</subject><subject>Neoplasms, Multiple Primary - drug therapy</subject><subject>Neoplasms, Multiple Primary - mortality</subject><subject>Neoplasms, Multiple Primary - surgery</subject><subject>Organoplatinum Compounds - administration & dosage</subject><subject>Peritoneal Neoplasms - drug therapy</subject><subject>Peritoneal Neoplasms - mortality</subject><subject>Peritoneal Neoplasms - secondary</subject><subject>Peritoneal Neoplasms - surgery</subject><subject>Prognosis</subject><subject>Retrospective Studies</subject><subject>Sample Size</subject><subject>Stomach Neoplasms - pathology</subject><subject>Surgery</subject><subject>Synchronous peritoneal carcinomatosis</subject><subject>Taxoids - administration & dosage</subject><subject>Treatment Outcome</subject><issn>0748-7983</issn><issn>1532-2157</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9Us2O0zAQthCIXQovwAH5yKXFP0mcIISEAuyuVAlEl7NlO1PqktjBdhbyfjwYjloQ4sDJY30_o5lvEHpKyYYSWr04buAY_YblekOKDSn5PXRJS87WjJbiProkoqjXoqn5BXoU45EQ0nDRPEQXTFDRNKy4RD_bOfkA3WSSvQO8m8IXCDMe-yni63mEkA4QBmvwjUtB5b9N3oHqcXuAwS-gGmf83aYD3nqtxl4l67ByHX7rDST1A3qcPL4NoBLezc4cgnc-m3_8y0oFY50fVPLRRrwPfsBXKqaQ27bKGQgv8SeIU5_OoMrdrYMIuAWXIDxGD_aqj_Dk_K7Q5_fvbtvr9fbD1U37Zrs2RVmmNeWM0YJUlHGqtdG1rrui07zoKNMgVMUbsSeE66KuuNYNI3vWaCGYKmuaIb5Cz0--Y_DfJohJDjYa6HvlIM8kaU0K2lQiy1eInagm-BgD7OUY7KDCLCmRS3ryKJf05JKeJIXM6WXRs7P_pAfo_kh-x5UJr04EyFPeWQgyGgt5Q50NYJLsvP2__-t_5Ka3zhrVf4UZ4tFPweX9SSojk0TulvtZzodWnFBaCP4LdbXFWA</recordid><startdate>20160701</startdate><enddate>20160701</enddate><creator>Wu, Hai-Tao, MD</creator><creator>Peng, Kai-Wen, MD</creator><creator>Ji, Zhong-He, MD</creator><creator>Sun, Jian-Hua, MD</creator><creator>Zhang, Qian, MD</creator><creator>Yang, Xiao-Jun, MD, PhD</creator><creator>Huang, Chao-Qun, MD, PhD</creator><creator>Li, Yan, MD, PhD</creator><general>Elsevier Ltd</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-6018-6538</orcidid></search><sort><creationdate>20160701</creationdate><title>Cytoreductive Surgery plus Hyperthermic Intraperitoneal Chemotherapy with Lobaplatin and Docetaxel to Treat Synchronous Peritoneal Carcinomatosis from Gastric Cancer: Results from a Chinese Center</title><author>Wu, Hai-Tao, MD ; Peng, Kai-Wen, MD ; Ji, Zhong-He, MD ; Sun, Jian-Hua, MD ; Zhang, Qian, MD ; Yang, Xiao-Jun, MD, PhD ; Huang, Chao-Qun, MD, PhD ; Li, Yan, MD, PhD</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c455t-132214061231bbcb8b8d4db34d12be7a6397f003b4863bb920f29b772a58197f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Antineoplastic Combined Chemotherapy Protocols - adverse effects</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Carcinoma - drug therapy</topic><topic>Carcinoma - mortality</topic><topic>Carcinoma - secondary</topic><topic>Carcinoma - surgery</topic><topic>Chemotherapy, Cancer, Regional Perfusion</topic><topic>China</topic><topic>Cyclobutanes - administration & dosage</topic><topic>Cytoreduction Surgical Procedures</topic><topic>Cytoreductive surgery</topic><topic>Databases, Factual</topic><topic>Docetaxel</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Gastric cancer</topic><topic>Hematology, Oncology and Palliative Medicine</topic><topic>Humans</topic><topic>Hyperthermia, Induced</topic><topic>Hyperthermic intraperitoneal chemotherapy</topic><topic>Kaplan-Meier Estimate</topic><topic>Lobaplatin</topic><topic>Lymphatic Metastasis</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Neoplasm Invasiveness</topic><topic>Neoplasm Recurrence, Local</topic><topic>Neoplasm Staging</topic><topic>Neoplasms, Multiple Primary - drug therapy</topic><topic>Neoplasms, Multiple Primary - mortality</topic><topic>Neoplasms, Multiple Primary - surgery</topic><topic>Organoplatinum Compounds - administration & dosage</topic><topic>Peritoneal Neoplasms - drug therapy</topic><topic>Peritoneal Neoplasms - mortality</topic><topic>Peritoneal Neoplasms - secondary</topic><topic>Peritoneal Neoplasms - surgery</topic><topic>Prognosis</topic><topic>Retrospective Studies</topic><topic>Sample Size</topic><topic>Stomach Neoplasms - pathology</topic><topic>Surgery</topic><topic>Synchronous peritoneal carcinomatosis</topic><topic>Taxoids - administration & dosage</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wu, Hai-Tao, MD</creatorcontrib><creatorcontrib>Peng, Kai-Wen, MD</creatorcontrib><creatorcontrib>Ji, Zhong-He, MD</creatorcontrib><creatorcontrib>Sun, Jian-Hua, MD</creatorcontrib><creatorcontrib>Zhang, Qian, MD</creatorcontrib><creatorcontrib>Yang, Xiao-Jun, MD, PhD</creatorcontrib><creatorcontrib>Huang, Chao-Qun, MD, PhD</creatorcontrib><creatorcontrib>Li, Yan, MD, PhD</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of surgical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wu, Hai-Tao, MD</au><au>Peng, Kai-Wen, MD</au><au>Ji, Zhong-He, MD</au><au>Sun, Jian-Hua, MD</au><au>Zhang, Qian, MD</au><au>Yang, Xiao-Jun, MD, PhD</au><au>Huang, Chao-Qun, MD, PhD</au><au>Li, Yan, MD, PhD</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cytoreductive Surgery plus Hyperthermic Intraperitoneal Chemotherapy with Lobaplatin and Docetaxel to Treat Synchronous Peritoneal Carcinomatosis from Gastric Cancer: Results from a Chinese Center</atitle><jtitle>European journal of surgical oncology</jtitle><addtitle>Eur J Surg Oncol</addtitle><date>2016-07-01</date><risdate>2016</risdate><volume>42</volume><issue>7</issue><spage>1024</spage><epage>1034</epage><pages>1024-1034</pages><issn>0748-7983</issn><eissn>1532-2157</eissn><abstract>Abstract Background This work was to evaluate the efficacy and safety of cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) with lobaplatin and docetaxel to treat peritoneal carcinomatosis (PC) from gastric cancer (GC). Methods A total of 50 consecutive GC PC patients treated by 52 CRS+HIPEC procedures with lobaplatin 50 mg/m2 and docetaxel 60 mg/m2 in 6,000 mL of normal saline at (43±0.5) °C for 60 min. The primary endpoint was overall survival (OS), and the secondary endpoints were perioperative safety profiles. Results At the median follow-up of 22.5 (range, 5.1-50.7) months, the median OS was 14.3 (95% CI 7.6-21.0) months, and the 1-, 2-, and 3-year survival rates were 58%, 40%, and 32%, respectively. Mortality and serious adverse event (grade 3-5) morbidity rates in postoperative 30 days were 0.0% and 23.1%, respectively. Univariate analysis identified 4 parameters with significant effects on OS: completeness of cytoreduction (CC)0-1, normal (N) the preoperative tumor markers level (TM), adjuvant chemotherapy ≥6 cycles, and peritoneal cancer index ≤20. However, multivariate analysis identified CC0-1, perioperative TM (N), adjuvant chemotherapy ≥6 cycles as the independent predictor for better survival. Conclusions CRS+HIPEC with lobaplatin and docetaxel to treat selected GC PC could improve OS, with acceptable perioperative safety.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>27179924</pmid><doi>10.1016/j.ejso.2016.04.053</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0001-6018-6538</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0748-7983 |
| ispartof | European journal of surgical oncology, 2016-07, Vol.42 (7), p.1024-1034 |
| issn | 0748-7983 1532-2157 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1804196786 |
| source | MEDLINE; ScienceDirect Journals (5 years ago - present) |
| subjects | Adult Aged Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Carcinoma - drug therapy Carcinoma - mortality Carcinoma - secondary Carcinoma - surgery Chemotherapy, Cancer, Regional Perfusion China Cyclobutanes - administration & dosage Cytoreduction Surgical Procedures Cytoreductive surgery Databases, Factual Docetaxel Female Follow-Up Studies Gastric cancer Hematology, Oncology and Palliative Medicine Humans Hyperthermia, Induced Hyperthermic intraperitoneal chemotherapy Kaplan-Meier Estimate Lobaplatin Lymphatic Metastasis Male Middle Aged Neoplasm Invasiveness Neoplasm Recurrence, Local Neoplasm Staging Neoplasms, Multiple Primary - drug therapy Neoplasms, Multiple Primary - mortality Neoplasms, Multiple Primary - surgery Organoplatinum Compounds - administration & dosage Peritoneal Neoplasms - drug therapy Peritoneal Neoplasms - mortality Peritoneal Neoplasms - secondary Peritoneal Neoplasms - surgery Prognosis Retrospective Studies Sample Size Stomach Neoplasms - pathology Surgery Synchronous peritoneal carcinomatosis Taxoids - administration & dosage Treatment Outcome |
| title | Cytoreductive Surgery plus Hyperthermic Intraperitoneal Chemotherapy with Lobaplatin and Docetaxel to Treat Synchronous Peritoneal Carcinomatosis from Gastric Cancer: Results from a Chinese Center |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T18%3A41%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cytoreductive%20Surgery%20plus%20Hyperthermic%20Intraperitoneal%20Chemotherapy%20with%20Lobaplatin%20and%20Docetaxel%20to%20Treat%20Synchronous%20Peritoneal%20Carcinomatosis%20from%20Gastric%20Cancer:%20Results%20from%20a%20Chinese%20Center&rft.jtitle=European%20journal%20of%20surgical%20oncology&rft.au=Wu,%20Hai-Tao,%20MD&rft.date=2016-07-01&rft.volume=42&rft.issue=7&rft.spage=1024&rft.epage=1034&rft.pages=1024-1034&rft.issn=0748-7983&rft.eissn=1532-2157&rft_id=info:doi/10.1016/j.ejso.2016.04.053&rft_dat=%3Cproquest_cross%3E1804196786%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1804196786&rft_id=info:pmid/27179924&rft_els_id=1_s2_0_S0748798316301147&rfr_iscdi=true |